ArticleFrontiers in pharmacology2026
Antidepressant-like effects of Rg1 by mycn: promotion of neurogenesis in the hippocampus.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenoside Rg1 has been shown to have antidepressant effects by increasing hippocampal neurogenesis, but the molecular mechanisms remain unclear. In this research, we showed that Rg1 has antidepressant-like effects by increasing neurogenesis in the hippocampus, and these effects are achieved through Mycn. The evidence shows that Rg1 has antidepressant like effects in the tail suspension test, sucrose preference test. Moreover, Rg1 has anxiolytic-like effects in the O-maze test. In addition, Rg1 increases Mycn mRNA expression by q-PCR test. Mycn overexpression in the DG of ventral hippocampus is stress resilient. Furthermore, Mycn inhibition makes the mice more susceptible to depression and Rg1 cannot rescue this effect. In conclusion, Ginsenoside Rg1 targets Mycn to increase hippocampal neurogenesis to alleviate depressive-like behaviors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.